Business Wire09.16.20
SIA, a privately-held medical device manufacturer, has appointed Jason O’Hearn as chief commercial officer.
O’Hearn brings to SIA over 25 years of experience and a proven track record of developing and leading successful commercial organizations for aesthetic and regenerative medical devices. O’Hearn previously held executive roles of increasing responsibility within Sientra (SIEN) and Mentor Corporation WW LLC, a division of Johnson & Johnson (JNJ). He has led global sales, including both the introduction of new brands and the growth of market-leading devices, within the reconstructive and plastic surgery market.
“Jason has demonstrated the ability to create value and accumulate market share in the highly-competitive aesthetics market,” said Ryan Egeland, M.D., Ph.D., SIA investor and board director, “He brings a trusted name and a wealth of diverse but sector-specific expertise to the SIA management team during this important commercial transition for the company.”
Prior to joining SIA, O’Hearn was general manager and vice president of Aesthetics for Sientra Inc., responsible for its entire portfolio of breast implants, expanders, and scar treatments. He was promoted to that position after joining the company at the pre-revenue stage and launching multiple brands to achieve a peak market share of 17 percent within three years of launch. His business development expertise is grounded by direct customer interaction and sales early in his career with Mentor, where he went on to lead global sales for a business unit with $250 million annual revenue before joining Sientra.
O’Hearn earned a bachelor of arts degree in business management and a minor in finance from San Diego State University.
“I am very happy to join the talented and dedicated team at SIA,” said O’Hearn, regarding his new role. “Our flagship product, DuraSorb, will transform the use of soft tissue support to provide patients with long-lasting and predictable outcomes.”
O’Hearn brings to SIA over 25 years of experience and a proven track record of developing and leading successful commercial organizations for aesthetic and regenerative medical devices. O’Hearn previously held executive roles of increasing responsibility within Sientra (SIEN) and Mentor Corporation WW LLC, a division of Johnson & Johnson (JNJ). He has led global sales, including both the introduction of new brands and the growth of market-leading devices, within the reconstructive and plastic surgery market.
“Jason has demonstrated the ability to create value and accumulate market share in the highly-competitive aesthetics market,” said Ryan Egeland, M.D., Ph.D., SIA investor and board director, “He brings a trusted name and a wealth of diverse but sector-specific expertise to the SIA management team during this important commercial transition for the company.”
Prior to joining SIA, O’Hearn was general manager and vice president of Aesthetics for Sientra Inc., responsible for its entire portfolio of breast implants, expanders, and scar treatments. He was promoted to that position after joining the company at the pre-revenue stage and launching multiple brands to achieve a peak market share of 17 percent within three years of launch. His business development expertise is grounded by direct customer interaction and sales early in his career with Mentor, where he went on to lead global sales for a business unit with $250 million annual revenue before joining Sientra.
O’Hearn earned a bachelor of arts degree in business management and a minor in finance from San Diego State University.
“I am very happy to join the talented and dedicated team at SIA,” said O’Hearn, regarding his new role. “Our flagship product, DuraSorb, will transform the use of soft tissue support to provide patients with long-lasting and predictable outcomes.”